How does BOD's PS Ratio compare to its peers?

BOD is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (1.5x).

How does BOD's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

BOD is good value based on its Price-To-Sales Ratio (1.3x) compared to the Australian Pharmaceuticals industry average (4.9x).

What is BOD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate BOD's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of BOD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate BOD's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Bod Science (CHIA:BOD) - Stock Price, News & Analysis

BOD Stock Overview

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. More details

BOD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (A$4M)

Shares are highly illiquid

Earnings have declined by 4.2% per year over past 5 years

Negative shareholders equity

+ 2 more risks

Bod Science Limited Competitors

Avecho Biotechnology

ASX:AVE

AU$6.3m

Cann Global

ASX:CGB

AU$5.4m

Epsilon Healthcare

ASX:EPN

AU$7.2m

Argent BioPharma

ASX:RGT

AU$13.6m

Price History & Performance

Summary of all time highs, changes and price drops for Bod Science
Historical stock prices
Current Share Price	AU$0.024
52 Week High	AU$0.13
52 Week Low	AU$0.024
Beta	1.45
11 Month Change	0%
3 Month Change	-7.69%
1 Year Change	-64.18%
33 Year Change	-94.95%
5 Year Change	-94.84%
Change since IPO	-91.43%

Recent updates

Shareholder Returns

	BOD	AU Pharmaceuticals	AU Market
7D	0%	-7.0%	1.2%
1Y	-64.2%	34.9%	19.7%

Return vs Industry: BOD underperformed the Australian Pharmaceuticals industry which returned 59.7% over the past year.

Return vs Market: BOD underperformed the Australian Market which returned 4.4% over the past year.

Price Volatility

Is BOD's price volatile compared to industry and market?
BOD volatility
BOD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: BOD's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine BOD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Jo Patterson	bodscience.com

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets.

Bod Science Limited Fundamentals Summary

How do Bod Science's earnings and revenue compare to its market cap?
BOD fundamental statistics
Market cap	AU$4.26m
Earnings (TTM)	-AU$7.95m
Revenue (TTM)	AU$3.32m

1.3x

P/S Ratio

-0.5x

P/E Ratio

Is BOD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOD income statement (TTM)
Revenue	AU$3.32m
Cost of Revenue	AU$1.05m
Gross Profit	AU$2.27m
Other Expenses	AU$10.22m
Earnings	-AU$7.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.045
Gross Margin	68.40%
Net Profit Margin	-239.47%
Debt/Equity Ratio	-136.9%

How did BOD perform over the long term?

See historical performance and comparison

BOD Stock Overview

Risk Analysis

Bod Science Limited Competitors

ASX:AVE

AU$6.3m

ASX:CGB

AU$5.4m

ASX:EPN

AU$7.2m

ASX:RGT

AU$13.6m

Price History & Performance

Recent News & Updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

No independent directors

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

No independent directors

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New major risk - Negative shareholders equity

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

No independent directors

No independent directors

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Less than half of directors are independent

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Less than half of directors are independent

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Less than half of directors are independent

Less than half of directors are independent

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Less than half of directors are independent

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Less than half of directors are independent

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new and inexperienced directors

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

High number of new and inexperienced directors

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

High number of new and inexperienced directors

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

New 90-day low: AU$0.41

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.58

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.51

New 90-day high: AU$0.40

New 90-day high - AU$0.32

Full year earnings released - AU$0.054 loss per share

New 90-day low - AU$0.26

Shareholder Returns

Price Volatility

About the Company